Literature DB >> 2239121

Amrinone in perioperative low cardiac output syndrome.

G Fita1, C Gomar, M J Jimenez, M Pacheco, J Mulet, M A Nalda.   

Abstract

Amrinone has been shown to have a beneficial effect on left ventricular function in low output syndrome (LOS), but its use after open-heart surgery has not been extensively revised. We studied 10 patients with LOS post-cardiopulmonary bypass (CPB), who failed to respond to conventional treatment (vasoactive drugs plus intraaortic balloon pump) and were treated with amrinone, 0.75 mg.kg-1 followed by a continuous infusion of 5 to 10 micrograms.kg-1-min-1. One patient failed to respond to the treatment and subsequently died, but in the other nine patients blood pressure and cardiac index increased, left filling pressure decreased and they were successfully weaned from the CBP and survived. These results suggest that amrinone, either alone or combined with other inotropic drugs and mechanical support, is a valuable drug in the management of LOS after CPB.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2239121     DOI: 10.1111/j.1399-6576.1990.tb03128.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  3 in total

1.  Effects of concomitant usage of milrinone and catecholamine for weaning from cardiopulmonary bypass.

Authors:  Y Orime; M Shiono; H Hata; S Yagi; S Tsukamoto; S Kimura; S Ohmiya; A Sezai; H Yamada; M Obana; Y Sezai
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  1998-09

2.  Amrinone, in combination with norepinephrine, is an effective first-line drug for difficult separation from cardiopulmonary bypass.

Authors:  J F Hardy; N Searle; M Roy; J Perrault
Journal:  Can J Anaesth       Date:  1993-06       Impact factor: 5.063

3.  Safety of milrinone use in neonatal intensive care units.

Authors:  Samira Samiee-Zafarghandy; Sudha R Raman; John N van den Anker; Kerstin McHutchison; Christoph P Hornik; Reese H Clark; P Brian Smith
Journal:  Early Hum Dev       Date:  2014-11-26       Impact factor: 2.699

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.